undergoing peritoneal dialysis and hemodialysis, respectively. The glycated albumin (GA) levels were also significantly reduced compared with baseline in the peritoneal dialysis group, although the serum albumin levels did not change. The mean change in the GA level (DGA) was -3.4 ± 3.1% and -2.1 ± 2.5% among the patients undergoing peritoneal dialysis and hemodialysis, respectively. Stepwise multivariate analyses demonstrated the level of HbA1c at baseline to be significantly associated with the DHbA1c and that the level of GA at baseline was significantly associated with the DGA.
Conclusion:
Vildagliptin exhibits effectiveness in patients with type 2 diabetes mellitus undergoing peritoneal dialysis or hemodialysis.
INTRODUCTION
Diabetic nephropathy is a major vascular complication in patients with type 2 diabetes mellitus. The number of individuals undergoing maintenance dialysis due to diabetic nephropathy has risen to more than 100,000 in Japan [1] . It is important to manage the blood glucose level, even in diabetic patients undergoing maintenance dialysis, because good glycemic control prevents the development of diabetic macroangiopathy and improves prognosis [2] [3] [4] [5] . Hyperglycemia in patients with renal impairment is difficult to control due to limited therapeutic options and the high prevalence of diabetic complications. Although insulin injection is a basic therapy in patients with hyperglycemia and renal dysfunction, visual disturbances caused by diabetic retinopathy, hemiplegia secondary to cerebrovascular disease, and/or dementia, which is frequently observed in patients with diabetes [6] , are factors that limit the continuation of insulin therapy.
When oral hypoglycemic agents (OHAs) are prescribed for diabetic patients with renal insufficiency, sulfonylureas, biguanides, and thiazolidines should be used carefully due to side effects. Therefore, alpha-glucosidase inhibitors and glinides are used in such patients. However, glycemic control is often insufficient in diabetic patients with chronic renal failure as insulin resistance is commonly observed [7] .
Vildagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, is a novel OHA that can be used in patients with type 2 diabetes mellitus and renal impairment [8] [9] [10] . However, few reports have investigated the clinical effectiveness of vildagliptin in diabetic patients undergoing hemodialysis [11, 12] . Furthermore, no previous studies have evaluated the use of vildagliptin in patients undergoing peritoneal dialysis.
In the present study, the authors determined the clinical usefulness of vildagliptin for treating type 2 diabetic patients receiving chronic dialysis, including peritoneal dialysis.
MATERIALS AND METHODS

Ethics Statement
This study was conducted according to the principles expressed in the 2008 Declaration of
Helsinki. The Ethics Committee of Edogawa
Hospital approved the protocol of this study and waived the need for written informed consent because the data were analyzed anonymously for this study based on the information stored in the hospital database. 
Patients and Methods
Subjects
RESULTS
Patients Demographics and Baseline Characteristics
Fifty-nine subjects with type 2 diabetes mellitus from 97 patients undergoing chronic dialysis were eligible for this study. Thirty-eight nondiabetic subjects and patients treated with insulin (n = 16), liraglutide (n = 2), pioglitazone Table 1 shows the baseline characteristics of the study subjects. The duration of dialysis was significantly longer in the vildagliptin group than in the control group. All subjects were treated with vildagliptin monotherapy for glycemic control during the follow-up period in the vildagliptin group.
Efficacy
In the vildagliptin group, the blood glucose levels did not change significantly during the follow-up period ( Table 2 ). The HbA1c levels were significantly reduced after the initiation of vildagliptin therapy in both the hemodialysis and peritoneal dialysis groups, whereas the hemoglobin levels did not change during the follow-up period. The mean DHbA1c was -0.6 ± 0.9% and -0.5 ± 0.7% among the patients undergoing peritoneal dialysis and hemodialysis, respectively. The GA levels were also significantly reduced compared with baseline in the peritoneal dialysis group, although the serum albumin levels did not change. The mean DGA was -3.4 ± 3.1% and -2.1 ± 2.5% among the patients undergoing peritoneal dialysis and hemodialysis, respectively. The blood glucose, HbA1c, and GA levels at the baseline were higher in the vildagliptin group than in the control group.
The blood glucose and HbA1c levels increased Among the vildagliptin-treated patients undergoing peritoneal dialysis, the DHbA1c exhibited a significant negative correlation with the HbA1c level at baseline (Fig. 1) , although it was not related to age, the duration of diabetes mellitus, the duration of dialysis, or the levels of hemoglobin, serum total protein, albumin, aspartate transaminase, alanine transaminase, creatinine, blood urea nitrogen, uric acid, or blood glucose. There were also significant negative correlations between the DGA and the levels of HbA1c and GA at baseline (Fig. 2) . 
DISCUSSION
This study demonstrated that vildagliptin is clinically effective for achieving glycemic control in patients with type 2 diabetes mellitus undergoing either peritoneal dialysis or hemodialysis. There are no investigations of the clinical usefulness of vildagliptin in diabetic patients undergoing peritoneal dialysis, whereas several studies have already been reported in those undergoing hemodialysis [11] [12] [13] . Kume et al. [11] reported that the daily administration [12] also demonstrated that the administration of vildagliptin at a dose of 50 mg/day for 24 weeks achieved a 0.47-point reduction in the levels of HbA1c from 6.5% and a 3.2-point reduction in the levels of GA from 22.3% among 11 subjects with type 2 diabetes undergoing hemodialysis out of 30 patients administered 50-100 mg of daily vildagliptin.
Furthermore, Terawaki et al. [13] showed that the daily administration of 50 mg of vildagliptin for a few days shortened the duration of hyperglycemia in ten diabetic patients undergoing hemodialysis, similar to the results achieved with the daily administration of 0.3 mg of liraglutide, a glucagon-like peptide (GLP)-1 receptor agonist. Fig. 1 Relationships between the changes in the HbA1c level (DHbA1c) following the administration of vildagliptin and the levels of HbA1c and GA at baseline in the type 2 diabetic patients undergoing peritoneal dialysis. HbA1c hemoglobin A1c, GA glycated albumin Fig. 2 Relationships between the changes in the GA level (DGA) following the administration of vildagliptin and the levels of HbA1c and GA at baseline in the type 2 diabetic patients undergoing peritoneal dialysis. HbA1c hemoglobin A1c, GA glycated albumin
It is difficult to simply compare these results due to the different basal values of hemoglobin and HbA1c; however, the reductions in the HbA1c levels observed in the present study and in the investigations of subjects undergoing hemodialysis cited above [11, 12] are smaller than those reported in diabetic patients without renal dysfunction [14] [15] [16] . The differences in the reduction of HbA1c between patients with and without renal impairment may be due to the shortened turnover of red blood cells in individuals with renal insufficiency, in addition to the basal value of HbA1c. In the present study, the DHbA1c and DGA following the administration of vildagliptin were associated with the basal values of HbA1c and GA, respectively.
Similarly, it has been reported that the hypoglycemic effects of DPP-4 inhibitors are dependent on the glycemic control observed at baseline in diabetic patients without renal dysfunction [15, 16] . The GA level has been described as being more useful as an index of glycemic control than the HbA1c level in diabetic subjects undergoing hemodialysis [17] [18] [19] [20] [21] . Because hypoalbuminemia is commonly detected in patients receiving peritoneal dialysis, it is difficult to determine the degree of control of blood glucose based on the GA level in patients with diabetes receiving peritoneal dialysis.
However, it has been reported that the HbA1c level significantly underestimates glycemic control relative to the GA level in both hemodialysis and peritoneal dialysis patients [22] . Although the effects of vildagliptin on the GA level have not been previously investigated, both the HbA1c and GA levels were reduced by the administration of vildagliptin in the present study.
Insulin injection is an essential therapy in patients with diabetes and renal dysfunction, based on the various side effects of OHAs. The present study is associated with limitations that should be kept in mind when interpreting the results. First, the present study evaluated preliminary data in a short-term observation of a small number of patients.
Second, the study investigated changes in glycemic control only. It is necessary to determine which vascular events are prevented by the administration of vildagliptin in a larger number of patients during a longer follow-up period.
CONCLUSION
Vildagliptin exhibits effectiveness in achieving glycemic control in patients with type 2 diabetes mellitus undergoing either peritoneal dialysis or hemodialysis. In the present study, 
